Balancing viral replication in spleen and liver determines the outcome of systemic virus infection
- PMID: 26666281
- DOI: 10.1055/s-0041-109631
Balancing viral replication in spleen and liver determines the outcome of systemic virus infection
Abstract
The innate immune system limits virus replication during systemic infection by producing type I interferons (IFN-I) but still has to allow viral replication to achieve maximal innate and adaptive immune activation. Some spleen and lymph node resident antigen presenting cells (APCs) show limited response to IFN-I due to expression of the endogenous inhibitor of IFN-I signaling, Usp18. Therefore, virus in this spleen niche replicates despite high levels of IFN-I. This enforced viral replication leads to an exorbitant propagation of viral antigens and viral RNA. Viral antigen leads to massive activation of the adaptive immune system, while viral RNA to activated innate immunity. In contrast to these APCs, liver resident Kupffer cells, take up most of the systemic virus and suppress its replication in response to IFN-I. In addition, virus specific CD8 + T cells which are primed in the spleen migrate to the liver and kill virus infected cells. In this review we discuss the different mechanisms, which influence immune activation in spleen and antiviral mechanisms in the liver and how they determine the outcome of virus infection.
© Georg Thieme Verlag KG Stuttgart · New York.
Similar articles
-
Two separate mechanisms of enforced viral replication balance innate and adaptive immune activation.J Autoimmun. 2016 Feb;67:82-89. doi: 10.1016/j.jaut.2015.10.004. Epub 2015 Nov 7. J Autoimmun. 2016. PMID: 26553386
-
Virus-specific antibodies allow viral replication in the marginal zone, thereby promoting CD8(+) T-cell priming and viral control.Sci Rep. 2016 Jan 25;6:19191. doi: 10.1038/srep19191. Sci Rep. 2016. PMID: 26805453 Free PMC article.
-
Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice.Hepatology. 2010 Jul;52(1):25-32. doi: 10.1002/hep.23640. Hepatology. 2010. PMID: 20578253
-
Innate immune response to viral infection.Cytokine. 2008 Sep;43(3):336-41. doi: 10.1016/j.cyto.2008.07.009. Epub 2008 Aug 9. Cytokine. 2008. PMID: 18694646 Review.
-
Noncytolytic control of viral infections by the innate and adaptive immune response.Annu Rev Immunol. 2001;19:65-91. doi: 10.1146/annurev.immunol.19.1.65. Annu Rev Immunol. 2001. PMID: 11244031 Review.
Cited by
-
Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication.Mol Ther Methods Clin Dev. 2022 Dec 28;28:190-207. doi: 10.1016/j.omtm.2022.12.013. eCollection 2023 Mar 9. Mol Ther Methods Clin Dev. 2022. PMID: 36700123 Free PMC article.
-
Sociality predicts individual variation in the immunity of free-ranging rhesus macaques.Physiol Behav. 2021 Nov 1;241:113560. doi: 10.1016/j.physbeh.2021.113560. Epub 2021 Aug 25. Physiol Behav. 2021. PMID: 34454245 Free PMC article.
-
Replication of Influenza A Virus in Secondary Lymphatic Tissue Contributes to Innate Immune Activation.Pathogens. 2021 May 19;10(5):622. doi: 10.3390/pathogens10050622. Pathogens. 2021. PMID: 34069514 Free PMC article.
-
Mutation in Irf8 Gene (Irf8R294C ) Impairs Type I IFN-Mediated Antiviral Immune Response by Murine pDCs.Front Immunol. 2021 Nov 17;12:758190. doi: 10.3389/fimmu.2021.758190. eCollection 2021. Front Immunol. 2021. PMID: 34867997 Free PMC article.
-
A physiologically based pharmacokinetic model for V937 oncolytic virus in mice.Front Pharmacol. 2023 Sep 13;14:1211452. doi: 10.3389/fphar.2023.1211452. eCollection 2023. Front Pharmacol. 2023. PMID: 37771727 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous